Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc is positioned favorably due to its focus on developing proprietary medicines for significant unmet medical needs, particularly in oncology and COVID-19 treatment. The company's current valuation appears attractive, reflecting a positive sentiment among analysts about its potential, as indicated by an upward adjustment in the 12-month price target based on net present value (NPV) analysis. Additionally, the anticipated achievement of key clinical milestones is expected to serve as a strong catalyst for the company’s stock, suggesting a positive trajectory moving forward.

Bears say

Atossa Therapeutics reported a net loss of $8.4 million, translating to an earnings per share (EPS) of $(0.07), which fell short of both internal estimates and consensus expectations of $(0.06). The company faces significant risks, including balance sheet and liquidity issues, potential failures of its drug candidates in demonstrating safety and efficacy during clinical trials, and challenges in securing regulatory approvals. Additionally, the ability to successfully commercialize its products and ensure suitable reimbursement remains uncertain amidst heightened competition and evolving investor sentiment toward biotechnology stocks.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.